282 related articles for article (PubMed ID: 20201608)
1. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
Guang-Sheng F; Mei-Lu B; Li-Nan C; Xiao-Ming C; Zi-Rong H; Zi-Yan H; Xiao-Ping J; Jian L; Shu-Ying W; Cheng-Liang X; Zheng-Ai X; Tian-Fu Y
Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
[TBL] [Abstract][Full Text] [Related]
2. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
Keam SJ; Wagstaff AJ
Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
[TBL] [Abstract][Full Text] [Related]
4. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
5. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
Anttila L; Kunz M; Marr J
Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
[TBL] [Abstract][Full Text] [Related]
6. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
[TBL] [Abstract][Full Text] [Related]
7. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
Anttila L; Neunteufel W; Petraglia F; Marr J; Kunz M
Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
[TBL] [Abstract][Full Text] [Related]
8. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
Parsey KS; Pong A
Contraception; 2000 Feb; 61(2):105-11. PubMed ID: 10802275
[TBL] [Abstract][Full Text] [Related]
9. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
[TBL] [Abstract][Full Text] [Related]
10. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of two monophase oral contraceptives with desogestrel].
Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
[TBL] [Abstract][Full Text] [Related]
14. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
[TBL] [Abstract][Full Text] [Related]
16. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
17. Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial.
Wongwananuruk T; Panichyawat N; Panchalee T; Jirakittidul P; Angsuwathana S; Sirimai K; Thamkhantho M; Chiravacharadej G
Eur J Contracept Reprod Health Care; 2020 Feb; 25(1):43-48. PubMed ID: 31756117
[No Abstract] [Full Text] [Related]
18. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
Mansour D
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
[TBL] [Abstract][Full Text] [Related]
19. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
20. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]